A drug that receives Fast Track designation may benefit from more frequent interactions with the FDA throughout drug development. In addition, the Fast Track program allows for Accelerated Approval ...

Retinitis Pigmentosa (RP), a genetic disorder, causes the progressive breakdown of rod cells, while cataracts (clouding of the eye’s lens), glaucoma (damage of the optic nerve), diabetic ...

Two new compounds may be able to treat retinitis pigmentosa, a group of inherited eye diseases that cause blindness. The compounds, described in a study published January 14 th in the open-access ...

a clinical-stage biopharmaceutical company developing treatments for retinitis pigmentosa, cataracts and other diseases caused by oxidative stress, today announced that the U.S. Food and Drug ...

Two new compounds may be able to treat retinitis pigmentosa, a group of inherited eye diseases that cause blindness. The compounds, described in a study published January 14 in the open-access ...

In retinitis pigmentosa, the rods and cones in the photoreceptors ... extensive compared to other eye procedures like ...

Nanoscope Therapeutics is on the brink of filing for FDA approval of what could be the first gene therapy for incurable eye disease retinitis pigmentosa (RP) that can be used regardless of ...